Avextra Supports First Fully EU-Funded Psilocybin Therapy Study, Now Approved by EMA
12 déc. 2024 07h00 HE
|
Avextra Pharma GmbH
Exclusive Industry Role: Avextra is the industry partner in the first EU-funded project focused on psychedelic-assisted therapy for patients in palliative care suffering from depression, with a total...
Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar
20 nov. 2024 07h00 HE
|
Avextra AG
Avextra Portugal launches an innovative in-house breeding program to develop proprietary cannabis varieties with specific, consistent and reproducible cannabinoid and terpene profiles.Over a two-year...
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases
08 oct. 2024 07h00 HE
|
Avextra AG
The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral...
Tilray Medical Launches Redecan Cannabis Brand in Australia
18 sept. 2024 07h00 HE
|
Tilray Brands, Inc.
Tilray's EU-GMP Certified Redecan Cannabis Now Available in Australia with Medical Prescription.
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances
20 juin 2024 01h00 HE
|
Avextra AG
Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines, is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...
Avextra und SynQube GmbH geben eine strategische Partnerschaft in der Arzneimittelentwicklung mit Cannabinoiden und anderen psychotropen Substanzen bekannt
20 juin 2024 01h00 HE
|
Avextra AG
Avextra, der führende europäische vertikal integrierte Hersteller und Entwickler von Medikamenten auf Cannabisbasis, erweitert nach Abschluss seiner Finanzierungsrunde im ersten Quartal 2024 seine...
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances
20 juin 2024 01h00 HE
|
Avextra AG
Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...
Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients
18 oct. 2023 07h00 HE
|
Avextra AG
Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the...
Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy
17 mai 2023 07h00 HE
|
Avextra AG
Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in ItalyAvextra extracts are the first Made in Germany products...
C15 Solutions Anticipates Substantial Growth in European Cannabis Market Through Innovative Tech Platform
20 avr. 2023 07h00 HE
|
C15 Solutions
Oakville, Ontario, April 20, 2023 (GLOBE NEWSWIRE) -- C15 Solutions (“C15” or the “Company”), a technology vendor delivering a customized eQMS (‘electronic Quality Management System’) for the...